The word “recursion” is the latest buzzword in AI circles. Two separate startups have taken on the name, and many more have started referencing recursive self-improvement (RSI) in their roadmaps. Like ...

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...